Marshall Wace LLP Acquires New Stake in Omnicell, Inc. (NASDAQ:OMCL)

Marshall Wace LLP bought a new position in shares of Omnicell, Inc. (NASDAQ:OMCL) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 59,972 shares of the company’s stock, valued at approximately $1,623,000. Marshall Wace LLP owned about 0.13% of Omnicell as of its most recent SEC filing.

A number of other large investors have also modified their holdings of OMCL. Arizona State Retirement System lifted its stake in shares of Omnicell by 2.9% in the second quarter. Arizona State Retirement System now owns 12,853 shares of the company’s stock worth $348,000 after buying an additional 357 shares in the last quarter. Texas Permanent School Fund Corp lifted its stake in Omnicell by 1.2% in the 1st quarter. Texas Permanent School Fund Corp now owns 39,630 shares of the company’s stock worth $1,158,000 after purchasing an additional 479 shares in the last quarter. Diversified Trust Co boosted its holdings in shares of Omnicell by 3.3% during the 2nd quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock worth $416,000 after purchasing an additional 494 shares during the last quarter. Louisiana State Employees Retirement System grew its position in shares of Omnicell by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock valued at $625,000 after purchasing an additional 600 shares in the last quarter. Finally, ProShare Advisors LLC increased its holdings in shares of Omnicell by 7.4% in the first quarter. ProShare Advisors LLC now owns 9,076 shares of the company’s stock valued at $265,000 after purchasing an additional 626 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Trading Up 2.1 %

NASDAQ OMCL opened at $42.39 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.45 and a quick ratio of 2.22. The stock has a market capitalization of $1.95 billion, a P/E ratio of -92.15, a PEG ratio of 47.43 and a beta of 0.83. The firm’s 50-day moving average is $42.08 and its two-hundred day moving average is $33.32. Omnicell, Inc. has a 12 month low of $25.12 and a 12 month high of $46.05.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.51 EPS for the quarter, topping the consensus estimate of $0.14 by $0.37. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The firm had revenue of $276.80 million for the quarter, compared to analyst estimates of $254.41 million. During the same period in the prior year, the business posted $0.29 EPS. The business’s revenue for the quarter was down 7.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Omnicell, Inc. will post 0.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on OMCL. Bank of America boosted their price objective on Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Barclays raised shares of Omnicell from an “underweight” rating to an “equal weight” rating and boosted their price target for the company from $26.00 to $39.00 in a research report on Friday, August 2nd. Wells Fargo & Company raised their price objective on shares of Omnicell from $26.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Friday, August 2nd. StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a report on Thursday, September 19th. Finally, JPMorgan Chase & Co. raised their price target on shares of Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a report on Friday, August 23rd. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Omnicell currently has a consensus rating of “Hold” and an average target price of $37.83.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.